{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:47:27Z","timestamp":1785822447787,"version":"3.56.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>Messenger RNA (mRNA) vaccine technology is often portrayed as a pandemic-era innovation for infectious disease control, but this perspective no longer reflects its expanding clinical and societal significance. Although global attention intensified during the SARS-CoV-2 pandemic, mRNA platforms are founded on more than three\u00a0decades of pre-pandemic research in cancer immunotherapy and experimental vaccinology. Emerging evidence demonstrates that programmable RNA technologies can extend beyond pathogen prevention into oncology, immune modulation, protein replacement, cardiovascular risk reduction, and population-level preventive medicine. Nevertheless, existing literature remains fragmented across disciplines and lacks a unifying framework explaining how a single platform can simultaneously support prevention, therapy, and health-system resilience. This narrative review addresses this gap by synthesising literature from PubMed, Scopus, and Web of Science, emphasising studies published between 2018 and 2025 while retaining seminal pre-2018 mechanistic contributions. We integrate mechanistic, translational, and policy evidence to propose that mRNA vaccines should be reconceptualised as adaptive health infrastructure rather than single-purpose biologics. We introduce the Adaptive Preventive Therapeutics Continuum (APTC), a framework positioning mRNA intervention along a spectrum from anticipatory prevention to chronic disease management and precision restoration of physiological function. The central innovation of mRNA technology lies not only in rapid manufacturing but also in its programmable temporality the capacity to generate transient, titratable, and updateable biological responses tailored to disease stage and population need, thereby supporting resilient and adaptable healthcare systems.<\/jats:p>","DOI":"10.3389\/fbioe.2026.1869761","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:38:43Z","timestamp":1785821923000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From pathogen defence to precision health infrastructure: mRNA vaccines beyond infectious disease in preventive health, chronic disease management, and population wellbeing"],"prefix":"10.3389","volume":"14","author":[{"given":"Okechukwu Paul-Chima","family":"Ugwu","sequence":"first","affiliation":[{"name":"Department of Research, Publication and Extension, Kampala International University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyere Nneoma","family":"Ugwu","sequence":"additional","affiliation":[{"name":"Department of Research, Publication and Extension, Kampala International University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godson Emeka","family":"Anyanwu","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Biomedical Sciences, Kampala International University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Basajja","sequence":"additional","affiliation":[{"name":"Department of Research, Publication and Extension, Kampala International University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31780","DOI":"10.1021\/acsnano.4c06667","article-title":"Engineered immune constructs alter antigen-specific immune tolerance and confer durable protection in myelin-driven autoimmunity","volume":"18","author":"Ackun-Farmmer","year":"2024","journal-title":"ACS Nano"},{"key":"B2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/cp9.0000000000000118","article-title":"Harnessing mRNA technology for ischemic heart disease: a review of regenerative and protective therapies","volume":"10","author":"Adjmi","year":"2025","journal-title":"Cardiol. Plus"},{"key":"B3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.molmed.2021.05.004","article-title":"mRNA therapeutics: beyond vaccine applications","volume":"27","author":"Bhat","year":"2021","journal-title":"Trends Mol. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/HCO.0000000000000850","article-title":"RNA therapeutics for cardiovascular disease","volume":"36","author":"Boada","year":"2021","journal-title":"Curr. Opin. Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jconrel.2024.09.020","article-title":"LNP-mRNA vaccine prevents type 1 diabetes in Non-obese diabetic mice","volume":"375","author":"Chen","year":"2024","journal-title":"J. Control. Release"},{"key":"B10","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s43587-025-00895-1","article-title":"Using RNA therapeutics to promote healthy aging","volume":"5","author":"Chen","year":"2025","journal-title":"Nat. Aging"},{"key":"B11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2024.01.028","article-title":"Current RNA strategies in treating cardiovascular diseases","volume":"32","author":"Chia","year":"2024","journal-title":"Mol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s00296-024-05734-x","article-title":"Safety, efficacy, and immunogenicity of SARS-CoV-2 mRNA vaccination in children and adult patients with rheumatic diseases","volume":"44","author":"Dhanasekaran","year":"2024","journal-title":"Rheumatol. Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2477300","DOI":"10.1080\/07853890.2025.2477300","article-title":"Age-related changes in the immune system and challenges for the development of age-specific vaccines","volume":"57","author":"Doherty","year":"2025","journal-title":"Ann. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1161\/CIRCULATIONAHA.123.067373","article-title":"RNA therapeutics for the cardiovascular system","volume":"149","author":"Dzau","year":"2024","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e010569","DOI":"10.1136\/jitc-2024-010569","article-title":"Leveraging mRNA technology for antigen-based immuno-oncology therapies","volume":"13","author":"Floudas","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s42358-023-00316-0","article-title":"Prevalence and factors associated with flares following COVID\u201019 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study","volume":"63","author":"Fong","year":"2023","journal-title":"Adv. Rheumatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in patients with autoimmune rheumatic diseases","volume":"80","author":"Furer","year":"2021","journal-title":"Ann. Rheumatic Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"17721","DOI":"10.1021\/acsnano.3c00958","article-title":"Modulating plaque inflammation via targeted mRNA nanoparticles for the treatment of atherosclerosis","volume":"17","author":"Gao","year":"2023","journal-title":"ACS Nano"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1002\/mco2.167","article-title":"mRNA vaccines in the prevention and treatment of diseases","volume":"3","author":"Gu","year":"2022","journal-title":"MedComm"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1547025","DOI":"10.3389\/fbioe.2025.1547025","article-title":"mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy","volume":"13","author":"Haghmorad","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1016\/j.ymthe.2022.08.024","article-title":"Anti-atherosclerotic therapies: milestones, challenges, and emerging innovations","volume":"30","author":"Hetherington","year":"2022","journal-title":"Mol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/s43587-025-00939-6","article-title":"Understanding and improving vaccine efficacy in older adults","volume":"5","author":"Hofer","year":"2025","journal-title":"Nat. Aging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"vkaf283.156","DOI":"10.1093\/jimmun\/vkaf283.156","article-title":"Immune regulation by mRNA: inducing antigen-specific regulatory T cells for therapeutic applications","volume":"214","author":"Imai","year":"2025","journal-title":"J. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"145010","DOI":"10.1016\/j.ijbiomac.2025.145010","article-title":"Illuminating the shadows\u2010perspectives on mRNA vaccine adverse events\u2010mechanisms, risks and management: a review","volume":"318","author":"Kang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10557-020-07051-4","article-title":"Modified mRNA as a therapeutic tool for the heart","volume":"34","author":"Kaur","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"vkaf283.2357","DOI":"10.1093\/jimmun\/vkaf283.2357","article-title":"Antigen-specific tolerogenic mRNA-LNPs for the treatment of autoimmunity","volume":"214","author":"Kenison-White","year":"2025","journal-title":"J. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"107847","DOI":"10.1016\/j.phrs.2025.107847","article-title":"Messenger RNA (mRNA) based therapeutics in transforming cardiovascular care: Progress, regulatory challenges and future perspectives","volume":"218","author":"Khan","year":"2025","journal-title":"Pharmacol. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","article-title":"Recent advances in mRNA\u2010LNP therapeutics: immunological and pharmacological aspects","volume":"20","author":"Kiaie","year":"2022","journal-title":"J. Nanobiotechnology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/jcdd11020038","article-title":"Cell-specific mRNA therapeutics for cardiovascular diseases and regeneration","volume":"11","author":"Kishore","year":"2024","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/biochem5020005","article-title":"Advances in personalized cancer vaccine development: AI applications from neoantigen discovery to mRNA formulation","volume":"5","author":"Kong","year":"2025","journal-title":"Biochem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.74141","article-title":"Innovative mRNA vaccine approaches in targeting atherosclerosis","volume":"16","author":"Kumar","year":"2024","journal-title":"Cureus"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1093\/eurheartj\/ehaa229","article-title":"From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases","volume":"41","author":"Landmesser","year":"2020","journal-title":"Eur. Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","article-title":"Balancing immunogenicity and reactogenicity in mRNA vaccines","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. and Mol. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1384","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41551-025-01373-0","article-title":"Generation of tolerogenic antigen\u2010presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles","volume":"9","author":"Liu","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","article-title":"mRNA-based protein replacement therapy for the heart","volume":"27","author":"Magadum","year":"2018","journal-title":"Mol. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3390\/vaccines12111270","article-title":"Immune checkpoint inhibitors and vaccination: assessing safety, efficacy, and synergistic potential","volume":"12","author":"New","year":"2024","journal-title":"Vaccines"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.3390\/cancers14205163","article-title":"Neoantigen vaccines: clinical trials, classes, indications, adjuvants and combinatorial treatments","volume":"14","author":"Niemi","year":"2022","journal-title":"Cancers"},{"key":"B46","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2013 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"7779","DOI":"10.7150\/thno.111503","article-title":"Harnessing mRNA for heart health: a new era in cardiovascular treatment","volume":"15","author":"Peng","year":"2025","journal-title":"Theranostics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014Developing a new class of drugs","volume":"13","author":"\u015eahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"85.11","DOI":"10.4049\/jimmunol.210.supp.85.11","article-title":"Harnessing regulatory T cells by mRNA-induced antigen specificity","volume":"210","author":"Scott","year":"2023","journal-title":"J. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40364-024-00692-9","article-title":"mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy","volume":"12","author":"Shariati","year":"2024","journal-title":"Biomark. Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in preclinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","article-title":"Lipid nanoparticle-mediated mRNA delivery in cardiovascular diseases","volume":"372","author":"Soroudi","year":"2024","journal-title":"J. Control. Release"},{"key":"B58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13073-024-01281-z","article-title":"mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors","volume":"16","author":"Trivedi","year":"2024","journal-title":"Genome Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"B60","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12929-023-00977-5","article-title":"mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications","volume":"30","author":"Wang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"09636897241248956","DOI":"10.1177\/09636897241248956","article-title":"Potential application of modified mRNA in cardiac regeneration","volume":"33","author":"Wang","year":"2024","journal-title":"Cell. Transplant."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2412543","DOI":"10.1002\/advs.202412543","article-title":"A spleen-targeted tolerogenic mRNA-LNP vaccine for experimental asthma","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.molpharmaceut.2c00010","article-title":"Current status and future perspectives on mRNA drug manufacturing","volume":"19","author":"Webb","year":"2022","journal-title":"Mol. Pharm."},{"key":"B64","doi-asserted-by":"publisher","first-page":"107534","DOI":"10.1016\/j.biotechadv.2020.107534","article-title":"The challenge and prospect of mRNA therapeutics landscape","volume":"40","author":"Weng","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"B65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.3390\/ijms21186582","article-title":"mRNA vaccine era \u2013 mechanisms, drug platform and clinical prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.medj.2024.11.015","article-title":"Clinical advances of mRNA vaccines for cancer immunotherapy","volume":"6","author":"Yaremenko","year":"2025","journal-title":"Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3390\/cells14181476","article-title":"Next-generation mRNA vaccines in melanoma: advances in delivery and combination strategies","volume":"14","author":"Zoroddu","year":"2025","journal-title":"Cells"}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1869761\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:38:44Z","timestamp":1785821924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1869761\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":69,"alternative-id":["10.3389\/fbioe.2026.1869761"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2026.1869761","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1869761"}}